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Background:  Paroxysmal  nocturnal  dyspnea  (PND)  is  a  common  symptom  for patients  with  acute  decom-
pensated  heart  failure  (ADHF).  Some  symptoms  of  PND  are  similar  to  those  of  sleep apnea  (SA)  which
might  be  associated  with  overnight  worsening  hemodynamics  in failing  hearts.  However,  the  associa-
tion  between  PND,  SA,  and  overnight  change  in hemodynamics  in  patients  with  heart  failure  remains
uncertain.
Methods:  We  studied  28  consecutive  patients  with  reduced  ejection  fraction  who  were  hospitalized  with
ADHF.  Plasma  atrial  natriuretic  peptide  (ANP)  levels  were  measured  before  and  after  overnight  sleep
study. PND  was  deﬁned  as  having  an episode  of PND  prior  to hospitalization  for  ADHF.
Results:  Ten  (36%)  patients  had a history  of  PND.  Respiratory  disturbance  index  (the  frequency  and  severitybstructive sleep apnea of sleep  apnea)  was  an  independent  factor  associated  with  a history  of  PND  (odds  ratio  1.24,  95% con-
ﬁdence  interval  1.05–1.47,  p  = 0.011).  In those  without  PND,  plasma  ANP  levels  decreased  from  before
sleep  to after  waking,  whereas  in  those  with  PND  it increased  (p = 0.011).  In  addition,  overnight  change
in  plasma  ANP  levels  was  independently  associated  with  respiratory  disturbance  index  (p  =  0.035).
Conclusion:  These  results  thus  suggest  that in  patients  with  ADHF,  SA  might  be a predisposing  cause  of
PND  in association  with  overnight  worsening  hemodynamics.
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Acute decompensated heart failure (ADHF) is a common and
rowing medical problem associated with major morbidity and
ortality [1]. The difﬁculties surrounding treatment begin with a
ack of clear deﬁnitions. Because of the heterogeneous nature of
DHF, no single ﬁnding is deﬁnitive for diagnosis, and instead a
road array of signs and symptoms are associated with the condi-
ion. Of the associated symptoms in patients with ADHF, dyspnea on
xertion is the most sensitive, whereas paroxysmal nocturnal dys-
nea (PND) is the most speciﬁc [2], and is characterized by “patient
wakens, often quite suddenly and with a feeling of severe anxiety
nd suffocation, sits bolt upright, and gasps for breath” [3]. Thus,
ND is a common symptom among patients with ADHF. Relieving a
ypical symptom as a focus of treatment for heart failure (HF) could
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lead to improved quality of life and be important as a therapeutic
target. However, the pathophysiology of PND remains unknown.
It is therefore important to achieve a better understanding of PND
which might contribute to improving the clinical course. Coexisting
sleep apnea (SA) may  be a factor in PND.
Some symptoms of PND are similar to those of SA. SA is more
common in patients with ﬂuid retention such as in HF than in those
without [4,5]. A previous study showed the possibility that rostral
ﬂuid displacement from edematous legs to the neck and lung upon
assuming the recumbent position could predispose to obstructive
and central apnea during sleep [6]. In addition, pulmonary capil-
lary wedge pressure (PCWP) in patients with HF is associated with
central apnea [7]. Therefore, excess ﬂuid volume and worsening
hemodynamics could be important factors coexisting with SA in
patients with HF. On the other hand, SA is characterized by recur-
rent hypoxia, arousal, and the generation of exaggerated negative
intrathoracic pressure during sleep, which increases sympathetic
nervous system activity, reduces cardiac parasympathetic activity,
and causes repetitive surges in heart rate, blood pressure, and left
ventricular preload and afterload. The mechanical loading of the
myocardium can also increase myocardial oxygen demand in the
face of a reduced supply, causing a decrease in cardiac output in
vier Ltd. All rights reserved.
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atients with HF [8,9]. Therefore, the failing heart could also be
usceptible to the adverse hemodynamic consequences of SA.
Thus, it is likely that the pathophysiology of PND may  be asso-
iated with SA through worsening hemodynamics during sleep in
atients with HF. However, the relationship among PND, SA, and
vernight change in hemodynamics in patients with HF remains
ncertain. A number of studies have shown that plasma atrial natri-
retic peptide (ANP) levels are elevated in patients with HF, which
re positively correlated with right atrial pressure (RAP) or PCWP,
r both [10,11]. Therefore, plasma ANP levels could be useful as a
ardiac biomarker predicting overnight changes in general hemo-
ynamics in patients with HF. We  hypothesized that coexisting SA
n patients referred for ADHF might be associated with PND accom-
anied by increased plasma ANP levels at baseline and its overnight
ncrement during pathologic sleep disturbance.
ethods
atients and study design
We  prospectively recruited consecutive HF patients with
educed ejection fraction who were hospitalized with ADHF in
ur institute between May  1, 2006 and October 30, 2006. After
heir conditions had been improved by medical treatment and their
F had been stabilized [New York Heart Association (NYHA) class
I and III], each patient underwent complete assessment during
vernight sleep. Plasma ANP levels were measured before and after
he overnight sleep study.
Inclusion criteria were: (1) age 18 years or older and (2)
eft ventricular ejection fraction (LVEF) ≤ 40% as conﬁrmed by
chocardiography. Exclusion criteria included: (1) unstable status,
ncluding unstable angina, NYHA class IV, receiving any intravenous
rip infusions, oxygen supplementation, or positive airway pres-
ure treatment; (2) hospitalization with acute coronary syndrome;
3) congenital heart disease; and (4) having renal dysfunction
eﬁned as an estimated glomerular ﬁltration rate < 60 ml/min,
ecause renal function directly contributes to elevated natriuretic
eptide levels [12]. No patients were selected on the basis of possi-
le underlying SA. The study was approved by the local institutional
eview boards and all patients gave written informed consent for
articipation in the study.
ata collection
Data on demographic characteristics, medical history, and
edication use were obtained with the use of a standardized ques-
ionnaire and patient medical records obtained by a physician at
he time of the sleep study. PND was deﬁned as having an episode
hat ‘patient suddenly awakens with a feeling of suffocation or a
asp for breath’ prior to hospitalization for ADHF. Atrial ﬁbrillation
as deﬁned by its presence on the continuous electrocardiographic
ecording during the sleep study. LVEF was determined using Simp-
on’s method with echocardiography in the stable condition. Right
atheterization was performed by experienced cardiologists on the
ay of the sleep study.
Plasma ANP levels were determined in samples obtained at
2:00 (before sleep) and 06:00 (after waking). The patients lay qui-
tly for at least 30 min  before the baseline samples were collected
efore sleep. At the end of the sleep study, samples were collected
mmediately after the patients awoke, but before they arose from
ed. Blood was ﬁrst collected in a heparinized plastic syringe to
lear the tubing volume. Thereafter, the blood samples collected
or the determination of ANP were transferred to chilled disposable
ubes containing aprotinin and ethylenediaminetetraacetic acid
nd immediately centrifuged. The plasma was then frozen at −20 ◦C Cardiology 61 (2013) 348–353 349
and stored until quantitative ANP analysis was performed. Plasma
ANP levels were measured using a standard peptide radioim-
munoassay kit (Shionogi ANP kit, Shionogi & Co., Ltd., Osaka, Japan).
Sleep study
The overnight sleep study was performed using a cardiopul-
monary monitoring device (Morpheus, Teijin Inc., Tokyo, Japan)
consisting of a pressure sensor for nasal ﬂow, two stress-sensitive
belts for the ribcage and abdomen, respectively, and a continuous
pulse oximeter. An episode of apnea was  deﬁned as the com-
plete cessation of the sum of thoracoabdominal movements and
air ﬂow for ≥10 s. An episode of hypopnea was deﬁned as a ≥50%
decrease in the sum of thoracoabdominal movements and air ﬂow
lasting for ≥10 s, followed by a reduction in SaO2 of at least 4%.
Apnea was  classiﬁed as obstructive or central in the presence or
absence of ﬂow and thoracoabdominal motion, respectively, and
hypopnea as obstructive or central in the presence or absence
of out-of-phase thoracoabdominal motion, respectively [13]. The
total respiratory disturbance index (RDI) was quantiﬁed as the total
frequency of apnea and hypopnea per hour of time in bed and sub-
classiﬁed into either central-RDI or obstructive-RDI based on the
above deﬁnitions. The sleep study was manually analyzed by an
expert technician who was  blinded to the patients’ baseline clinical
characteristics.
Statistical analysis
Comparisons between the two  groups were performed using
Student’s t-test for continuous variables that were normally dis-
tributed and the Mann–Whitney U-test for variables that were
not normally distributed. The chi-square or Fisher’s exact test
was used to compare nominally scaled variables. To evaluate
the independent factors associated with PND, multivariate anal-
ysis was performed using the logistic regression model with the
best subset variable selection method including older age, male
sex, body mass index, LVEF, atrial ﬁbrillation, ischemic etiology,
and total RDI. To determine the independent factors associated
with RDI, multivariate analysis was  performed using the gen-
eralized linear regression model with the best subset variable
selection method including older age, male sex, body mass index,
LVEF, atrial ﬁbrillation, ischemic etiology, plasma ANP level before
sleep, and overnight change in plasma ANP level. Odds ratios
(ORs) and regression coefﬁcients are reported with 95% conﬁ-
dence intervals (CIs). The best cutoff values for variables predicting
increasing plasma ANP levels during overnight sleep were iden-
tiﬁed based on receiver operating characteristic (ROC) curves
at regular intervals as the value that minimized the expression
[(1 − sensitivity)2 + (1 − speciﬁcity)2] [14]. Data are presented as
mean ± SD or SEM unless indicated otherwise. The inﬂuence of
proﬁle, linearity, interaction, and collinearity was assessed in all
models by regression diagnostic analysis. A two-tailed p-value of
less than 0.05 was  considered to indicate a statistically signiﬁcant
difference. The analyses were performed using Statistical Analysis
System ver. 9.1 software (SAS Institute Inc., Cary, NC, USA).
Results
Of 50 consecutive hospitalized patients with ADHF, 23 patients
were excluded from the study: 2 patients died, 15 patients had
normal ejection fraction, 1 had congenital heart disease, 4 had renal
dysfunction, and 1 was  receiving supplemental oxygen. Thus, a total
of 28 patients hospitalized for ADHF were included in the ﬁnal anal-
ysis. There were 15 (54%) men  and 13 (46%) women, whose ages
ranged from 33 to 77 years (mean 59 ± 12 years), and whose body
mass index was 22.5 ± 2.9 kg/m2. Ten (36%) patients had a history
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Table  1
Patient characteristics in the presence and absence of PND.
Variable PND p-Value
No (N = 18) Yes (N = 10)
Age (years) 56 ± 13 64 ± 9 p = 0.118
Male (%) 9 (50) 6 (60) p = 0.627
Body mass index (kg/m2) 21.8 ± 2.3 23.7 ± 3.6 p = 0.100
Left ventricular ejection fraction (%) 30.2 ± 11.5 21.6 ± 9.5 p = 0.056
Left ventricular diastolic diameter (mm)  62.1 ± 11.2 67.6 ± 9.5 p = 0.201
Atrial ﬁbrillation (%) 7 (39) 5 (50) p = 0.586
Ischemic heart disease (%) 1 (6) 4 (40) p = 0.022
Medications
Thiazide or loop diuretics (%) 15 (83) 9 (90) p = 0.644
ACE inhibitors and/or ARB (%) 16 (89) 10 (100) p = 0.291
Beta-blockers (%) 17 (94) 10 (100) p = 0.467
Total RDI (no./h) 9.6 ± 7.7 24.4 ± 8.9 p < 0.001
Obstructive-RDI (no./h) 7.1 ± 6.2 8.8 ± 9.6 p = 0.570
Central-RDI (no./h) 2.5 ± 3.4 15.5 ± 12.6 p < 0.001
Lowest SaO2 (%) 86.4 ± 5.3 80.3 ± 5.1 p = 0.006
Values are expressed as mean ± SD or number (%).
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associated with RDI (Table 2). In addition, when total RDI was  sub-
T
U
T
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; PND,
aroxysmal nocturnal dyspnea; RDI, respiratory disturbance index.
f PND. All patients had NYHA class II and III, and mean LVEF was
7.1 ± 11.5%. There was a history of hypertension in 21% of patients
nd diabetes in 11%. The etiology of HF was ischemic in 18%. At
he time of assessment, 93% were taking angiotensin-converting
nzyme (ACE) inhibitors and/or angiotensin receptor blockers, 96%
eta-blockers, and 86% thiazide or loop diuretics. The period from
ospitalization to the sleep study ranged from 4 to 36 days (mean
4 ± 6 days). RDI ranged from 0.4 to 37.7/h (mean 14.9 ± 10.8/h).
The characteristics of the patients with and without PND are
hown in Table 1. Patients with PND had a signiﬁcantly higher per-
entage of ischemic etiology, higher total RDI and central-RDI, and
ower SaO2 than those without PND. Patients with PND tended
o be older, have a higher body mass index, and have a lower
VEF compared with those without PND. There were no differences
n the proportion of male sex, atrial ﬁbrillation, and medication
se between the two groups. In multivariate analysis using the
ogistic regression model with the best subset variable selection
ethod including older age, male sex, body mass index, LVEF, atrial
brillation, ischemic etiology, and total RDI, only total RDI was
n independent factor associated with a history of PND (per one
vent/h increase, OR 1.24, 95% CI 1.05–1.47, p = 0.011). The ROC
urve demonstrating the sensitivity and speciﬁcity of total RDI in
atients with HF shows that the best total RDI cutoff value to pre-
ict for PND was ≥20/h (area under the curve 0.88 ± 0.07, p < 0.001,
ensitivity 90.0%, speciﬁcity 88.9%).
Of the 28 patients analyzed, 20 underwent right catheterization
efore sleep study. Plasma ANP levels at baseline (before sleep)
igniﬁcantly correlated with RAP (y = 0.04x + 1.8, R = 0.55, p = 0.026)
nd PCWP (y = 0.09x + 4.5, R = 0.71, p = 0.002).
able 2
nivariate and multivariate analyses of factors associated with respiratory disturbance in
Variable Univariate 
Coefﬁcient (95% CI) 
Older age (per 10-yr increase) 4.72 (1.73–7.70) 
Male sex 11.70 (4.54–18.85) 
Body  mass index (kg/m2) 1.30 (–0.09–2.68) 
Left  ventricular ejection fraction (%) –0.15 (–0.52–0.23) 
Atrial ﬁbrillation 4.89 (–3.52–13.29) 
Ischemic heart disease 6.23 (0.80–12.43)
ANP before sleep (per 10-pg/ml increase) 0.71 (0.10–1.33) 
Overnight change in ANP (per 10-pg/ml increase) 0.81 (0.13–1.49) 
he above variables were all evaluated using the generalized linear regression model wit
NP,  atrial natriuretic peptide; 95% CI, 95% conﬁdence interval.Fig. 1. Plasma atrial natriuretic peptide (ANP) levels before sleep and after waking
(panel A), and overnight change in plasma ANP levels (panel B) in patients with and
without paroxysmal nocturnal dyspnea (PND).
Both plasma ANP levels obtained before sleep and after waking
were more than two-fold higher in patients with PND than in those
without (Fig. 1A). In addition, in the non-PND group, plasma ANP
levels decreased from before sleep to after waking, whereas in the
PND group it increased (Fig. 1B).
On univariate analysis, older age, male sex, ischemic heart
disease, plasma ANP level at baseline, and overnight change
in plasma ANP levels were positively associated with RDI. On
multivariate analysis, male sex, plasma ANP level before sleep,
and overnight change in plasma ANP levels were independentlyclassiﬁed into central- and obstructive-RDI, plasma ANP levels at
baseline associated with central-RDI (R = 0.52, p = 0.005), but not
with obstructive-RDI (R = 0.08, p = 0.690). And overnight change
dex.
Multivariate
p-Value Coefﬁcient (95% CI) p-Value
0.003
0.002 10.45 (4.40–16.50) 0.002
0.065
0.428
0.243
0.048
0.025 0.58 (0.09–1.06) 0.021
0.021 0.59 (0.05–1.12) 0.035
h the best subset variable selection method.
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aig. 2. Plasma atrial natriuretic peptide (ANP) levels before sleep and after waking
panel A), and overnight change in plasma ANP levels (panel B) in patients with
espiratory disturbance index (RDI) < 20 and RDI ≥ 20/h.
n plasma ANP levels was associated with central-RDI (R = 0.54,
 = 0.004).
Plasma ANP levels were higher in the RDI ≥ 20 group than in
he RDI < 20 group regardless of the sampling time point (Fig. 2A).
n addition, in the RDI < 20 group, the overnight change in plasma
NP levels showed a decreasing pattern, whereas in the RDI ≥ 20
roup it increased (Fig. 2B).
iscussion
This observational study yielded several novel observations.
irst, in patients referred for ADHF, the frequency and severity
f SA (total RDI) was an independent factor associated with the
resence of prior PND. Second, patients with PND had increased
NP levels at baseline and overnight increases in ANP; con-
ersely, those without PND did not. Third, we found that increased
NP at baseline and increasing overnight change in ANP were
ndependent factors associated with RDI. To the best of our
nowledge, this is the ﬁrst study that determined the rela-
ionship between PND and SA with a surrogate hemodynamic
arker.
The relationship between PND and SA was described in the930s by Harrison et al., who reported that the hyperpneic phase of
entral apnea could produce dyspnea [15]. On the other hand, Mon-
uschi reported four HF cases in which the symptoms of PND were
lleviated by volume reduction using diuretics [16]. Our results Cardiology 61 (2013) 348–353 351
provided further support for a direct link between PND, SA, and
overnight change in hemodynamics. In patients with HF, venous
return to the right heart at bedtime when moving from the upright
to the recumbent position is increased and this might lead to a
further worsening of hemodynamics including increased RAP and
PCWP [17,18]. Their conditions might predispose to central apnea
due to the stimulation of pulmonary irritant receptors that can
cause hyperventilation, which might then lead to PND. Indeed, a
previous study showed that in patients with HF, overnight ros-
tral ﬂuid displacement from the legs did not only contribute to
the pathogenesis of both obstructive and central SA, but also with
progressively greater overnight rostral ﬂuid shift, and there was
a gradation from no sleep apnea to obstructive SA to central SA
[6]. Solin et al. showed that PCWP and pulmonary artery pressure
were markedly higher in the central-predominant SA group than in
the obstructive-predominant SA and no SA groups when compar-
ing hemodynamics via right heart catheterization [7]. In addition,
positive airway pressure treatment and cardiac resynchronization
therapy reduced plasma ANP levels and the frequency and sever-
ity of SA through improvement of cardiac function in patients with
central SA [19,20]. Furthermore, a recent study showed that ANP
levels are increased among patients with HF and central SA com-
pared with those without CSA [21]. Our results were consistent
with those in the previous studies. The frequency and severity of
SA were positively correlated with plasma ANP levels at baseline
in central-RDI. Therefore, central apnea more likely arises as a con-
sequence of poor hemodynamics in HF than obstructive apnea. A
key factor predisposing to CSA is hyperventilation, setting eupneic
PaCO2 close to the apnea threshold. Hemodynamic congestion is
a signiﬁcant factor triggering hyperventilation and CSA. And other
factors, including impaired cerebral blood ﬂow, prolongation of cir-
culation time, metabolic alkalosis, low functional residual capacity,
upper airway instability, and hypoxia, may  further contribute to
respiratory instability and CSA.
On the other hand, SA itself might contribute to deteriorating
cardiac hemodynamics overnight in patients with HF. To our
knowledge, there has been no previous study of overnight changes
in hemodynamics among HF patients with and without SA. Nev-
ertheless, during obstructive apnea, the generation of exaggerated
negative intrathoracic pressure against the occluded upper airway,
hypoxia and hypercapnea, and sympathetic nerve activation leads
to increased right ventricular preload and increased left ventric-
ular afterload, both of which increase myocardial oxygen demand
[9,22], thereby causing distention of the right atrium and ventricle.
This distention also shifts the interventricular septum, impairs left
ventricular diastolic ﬁlling, and reduces stroke volume during each
apnea episode. Bradley et al. showed that during awake periods,
Mueller maneuvers were associated with signiﬁcantly greater
reductions in cardiac index in patients with HF than in healthy
individuals [9]. In severe apnea cases, the cycles of apnea can recur
several hundred times each night and could worsen hemodynam-
ics during overnight sleep. Also, as a result of these vacillations,
atrial intragranular stores of ANP are released immediately due
to intrathoracic pressure swings that modify the atrial distention
pressure, as our results showed [23–25]. In addition, short-term
randomized trials demonstrated that treating obstructive SA with
positive airway pressure in HF patients reduced sympathetic
nervous system activity, blood pressure, and nocturnal ventricular
ectopy, increased vagal modulation of the heart rate, and improved
LVEF and the quality of life [26–29]. In contrast to obstructive
apnea, in which inspiratory efforts are made against the occluded
upper airway owing to the continued presence of respiratory drive,
no respiratory effort is generated during central apnea due to the
cessation of respiratory drive. Thus, unlike obstructive apnea, no
negative intrathoracic pressure is generated during central apnea.
Therefore, its impact on afterload might be less than in obstructive
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pnea. However, it remains uncertain whether central apnea con-
ributes to the deterioration of cardiac hemodynamics overnight.
From these viewpoints, we suggest that in HF patients poor
emodynamics and a rostral ﬂuid shift at bedtime are important
actors causing SA, which itself constitutes an additive adverse
ffect on the worsening hemodynamics during sleep, and thus may
e closely associated with the predisposing to PND.
Our observations are subject to some limitations. First, the
resent study examined PND in patients who were in a stable con-
ition after a mean 14 days of hospitalization for initial ADHF.
Nevertheless, previous studies showed that the severity and
ypes of SA remained unchanged between decompensated and sta-
le HF status [30,31]. Second, the cardiorespiratory monitoring
evice used in this study cannot record electroencephalograms,
nlike polysomnography. However, the Morpheus device can dis-
inguish between obstructive and central apneas and hypopneas
nd like polysomnography meets the recommendations for the
uality of evidence obtained using methods for measuring breath-
ng disorders during sleep [32]. In addition, several reports showed
 close correlation between data obtained with polysomnography
nd this device [33]. Third, we only included patients with reduced
jection fraction. Further research is needed to determine associ-
tion between PND and SA for patients with preserved ejection
raction.
linical implications and conclusions
From a pathophysiologic viewpoint, it is likely that PND is asso-
iated with coexisting SA and worsening hemodynamics in patients
ith ADHF. From a therapeutic viewpoint, it may  be inferred from
he present results that interventions aiming at reducing plasma
NP levels and the frequency and severity of SA, independent of
peciﬁc treatment for cardiac hemodynamics, could help to relieve
ymptoms in patients with HF [34]. Increased LV ﬁlling pressure
s the main reason for ADHF admission and readmission. The goal
f tailored therapy for ADHF has been to reduce RAP and PCWP
lling pressures [35]. Therefore, our results suggest that treatment
or SA appears more likely to have beneﬁcial effects on symptoms
nd quality of life in HF patients. The presence of SA should thus be
etermined and treated as a target condition.
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